Bioxel Pharma Exceeds Financing Plan With Total Proceeds Of $7.4 Million

Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced that it has received $7.4 million in financing since February 2006.